Public Release: 

Drug halves risk of intestinal paralysis after abdominal surgery

Wiley

Recovery from abdominal surgery is often slowed by a temporary paralysis of the intestines known as ileus, but in a recent phase II clinical trial, prucalopride--a drug that stimulates motility--cut the risk of ileus lasting for more than 5 days in half.

In 110 patients undergoing abdominal surgery, only 16.4% of patients taking prucalopride for up to 7 days after surgery experienced ileus, compared with 34.5% of patients taking a placebo.

"Additional studies are warranted to validate our findings and assess the effect of prucalopride in patients with established prolonged post-operative ileus," said Prof. Weiming Zhu, co-author of the Alimentary Pharmacology & Therapeutics study.

###

Citation: Gong, J., Xie, Z., Zhang, T., Gu, L., Yao, W., Guo, Z., Li, Y., Lu, N., Zhu, W., Li, N. and Li, J. (2016), Randomised clinical trial: prucalopride, a colonic pro-motility agent, reduces the duration of post-operative ileus after elective gastrointestinal surgery. Alimentary Pharmacology & Therapeutics. doi: 10.1111/apt.13557

About Wiley

Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice and education. Through the Research segment, the Company provides digital and print scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising. The Professional Development segment provides digital and print books, online assessment and training services, and test prep and certification. In Education, Wiley provides education solutions including online program management services for higher education institutions and course management tools for instructors and students, as well as print and digital content. The Company's website can be accessed at http://www.wiley.com.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.